Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach-Reference-Cited by-同舟云学术

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

Published:2017-05-23 Issue:1 Volume:117 Page:25-32
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Kurokawa Yukinori,Yang Han-Kwang,Cho Haruhiko,Ryu Min-Hee,Masuzawa Toru,Park Sook Ryun,Matsumoto Sohei,Lee Hyuk-Joon,Honda Hiroshi,Kwon Oh Kyoung,Ishikawa Takashi,Lee Kyung Hee,Nabeshima Kazuhito,Kong Seong-Ho,Shimokawa Toshio,Yook Jeong-Hwan,Doki Yuichiro,Im Seock-Ah,Hirota Seiichi,Hahn Seokyung,Nishida Toshirou,Kang Yoon-Koo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017144.pdf

Reference30 articles.

1. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760–1764.

2. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620–625.

3. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY (2015) Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33: 4276–4283.

4. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753–1759.

5. Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 32: 1563–1570.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical Management of Gastric Gastrointestinal Stromal Tumors;Surgical Clinics of North America;2024-09

2. Utilization of neoadjuvant therapy for localized gastric gastrointestinal stromal tumors and the association with survival;Journal of Gastrointestinal Surgery;2024-09

3. Management of Gastrointestinal Stromal Tumors: An Update for Surgeons;Current Problems in Surgery;2024-09

4. Current Practice in the Diagnosis and Treatment of Localized Gastric Gastrointestinal Stromal Tumors;International Journal of Translational Medicine;2024-06-21

5. A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors;World Journal of Surgery;2024-05-17